University of Zurich
https://www.campus-schlieren.uzh.ch/en.html
8952 Schlieren, Wagistrasse 12
The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.
University of Zurich
Wagistrasse 12
8952 Schlieren
599 Ergebnisse für "promising" unter University of Zurich
UZH - Mathematisch-naturwissenschaftliche Fakultät - Promising trea...
... Promising treatment prospects for invasive breast cancer Scientists from the University of Zurich ... UZH - Mathematisch-naturwissenschaftliche Fakultät - Promising treatment prospects for invasive ... UZH - Mathematisch-naturwissenschaftliche Fakultät - Promising treatment prospects for invasive ... UZH - Mathematisch-naturwissenschaftliche Fakultät - Promising treatment prospects for invasive ...
UZH - Faculty of Science - Promising treatment prospects for invasi...
... Promising treatment prospects for invasive breast cancer Scientists from the University of Zurich ... UZH - Faculty of Science - Promising treatment prospects for invasive breast cancer ... UZH - Faculty of Science - Promising treatment prospects for invasive breast cancer Home Main ... UZH - Faculty of Science - Promising treatment prospects for invasive breast cancer ...
ETH Entrepreneurship
https://ethz.ch/en/industry/entrepreneurship.html
8952 Schlieren, Wagistrasse 18
Excellence in entrepreneurship at ETH Zurich is driven by world-class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions.
ETH Entrepreneurship
Wagistrasse 18
8952 Schlieren
697 Ergebnisse für "promising" unter ETH Entrepreneurship
Neural Correlates of Three Promising Endophenotypes of Depression: ...
... Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study ... Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study ... Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study ... Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study ... Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study ...
08 – Nanomaterials Engineering Research Group | ETH Zurich
... 3 NH 3 PbBr 3 2 PbBr 3 perovskites, leading to one of the most promising semiconductor materials ... CH(NH 2 ) 2 PbBr 3 perovskites, leading to one of the most promising semiconductor materials for next ...
Somagenetix
https://www.wysszurich.ch/projects/somagenetix
8952 Schlieren, Wagistrasse 23
Gene therapy solutions for patients with severe inherited diseases.
Somagenetix
Wagistrasse 23
8952 Schlieren
1418 Ergebnisse für "promising" unter Somagenetix
Reactive stability of promising scalable doped ceria materials for ...
... Reactive stability of promising scalable doped ceria materials for thermochemical two-step CO2 ... Reactive stability of promising scalable doped ceria materials for thermochemical two-step CO2 ... Reactive stability of promising scalable doped ceria materials for thermochemical two-step CO2 ...
Organometallic Derivatization of the Nematocidal Drug Monepantel Le...
... Organometallic Derivatization of the Nematocidal Drug Monepantel Leads to Promising Antiparasitic ... Organometallic Derivatization of the Nematocidal Drug Monepantel Leads to Promising Antiparasitic ... Organometallic Derivatization of the Nematocidal Drug Monepantel Leads to Promising Antiparasitic ...
Bio-Technopark Schlieren-Zürich
8952 Schlieren, Wagistrasse 23
+41 76 336 99 44
mario.jenni@bio-technopark.ch
The Bio-Technopark offers professional support for life science start-ups in the setting up and expansion of business activities and promotes interaction between start-ups, academia and industry. A nationally and internationally respected science park has grown up at Schlieren. Through stringent selection, coaching and support, more than 30 successful start-up companies with 750 employees are located here. Eight have been acquired by large corporates, but are still active in the park. Together with 20 institutes and clinics from the University and University Hospital Zurich, an innovative mix of very young and well-established companies and academic research groups has emerged.
Bio-Technopark Schlieren-Zürich
Wagistrasse 23
8952 Schlieren
18 Ergebnisse für "promising" unter Bio-Technopark Schlieren-Zürich
Positive MAPLE data for abicipar, promising research data for Molec...
... Positive MAPLE data for abicipar, promising research data for Molecular Partners’ innovative ... Positive MAPLE data for abicipar, promising research data for Molecular Partners’ innovative ... https://www.bio-technopark.ch/en/news-en/positive-maple-data-for-abicipar- promising-research-data ... Positive MAPLE data for abicipar, promising research data for Molecular Partners’ innovative ...
Molecular Partners Receives Orphan Drug Designation for MP0250 for ...
... scientific and clinical data submissions from sponsors to identify and designate products as promising for ... rare diseases and to further advance scientific development of such promising medical products. Orphan ... identify and designate products as promising for rare diseases and to further advance scientific ... development of such promising medical products. Orphan drug designation provides incentives for sponsors to ...
Molecular Partners AG
http://www.molecularpartners.com
8952 Schlieren, Wagistrasse 14
+41 44 755 77 00
Molecular Partners AG is a clinical-stage biopharmaceutical company, located in Schlieren, Switzerland, that is developing a new class of therapies known as DARPin® therapies.
Molecular Partners AG
Wagistrasse 14
8952 Schlieren
23 Ergebnisse für "promising" unter Molecular Partners AG
Comments on: Molecular Partners reports promising initial safety an...
... Comments on: Molecular Partners reports promising initial safety and efficacy data from its ongoing ... phase 2 study of MP0250 in multiple myeloma Comments on: Molecular Partners reports promising initial ... Comments on: Molecular Partners reports promising initial safety and efficacy data from its ongoing ... https://www.molecularpartners.com/molecular-partners-reports- promising-initial-safety-and-efficacy ... Comments on: Molecular Partners reports promising initial safety and efficacy data from its ongoing ...
MP and Roche start collaboration on the DRP Technology - Molecular ...
... bacteria, DARPins are one of the most promising non-antibody scaffolds for in vitro and in vivo ... collaboration with Roche is another strong sign for the promising potential of Molecular Partners’ technology ... their very favorable production properties in bacteria, DARPins are one of the most promising non ... promising potential of Molecular Partners’ technology and confirms our efforts to remain a leader in the ...
rqmicro AG
8952 Schlieren, Brandstrasse 24
+41 44 512 51 51
rqmicro’s separation and detection technology for microbiological tests in the water and food industry delivers reliable, quantitative and cost-effective results in less than 2 hours.
rqmicro AG
Brandstrasse 24
8952 Schlieren
Topadur Pharma AG
8952 Schlieren, Grabenstrasse 11a
A team dedicated to develop innovative speciality medication for the treatment of severe wound-healing problems enabling significant improvements of patients quality of life. TOPADUR’s lead R&D programs are local active, highly potent, dual mode of action drugs. TOPADUR’s unique development candidates #3;work on validated drug targets resulting in higher than average clinical success chances.
Topadur Pharma AG
Grabenstrasse 11a
8952 Schlieren
11 Ergebnisse für "promising" unter Topadur Pharma AG
TOPADUR Pharma AG ranked #58 in the 2016 TOP 100 Swiss Startups lis...
... promising Swiss startups are picked by top startup experts. Only 1 year after funding, TOPADUR Pharma AG ... promising Swiss startups are picked by top startup experts. Only 1 year after funding, TOPADUR Pharma AG ... achieved rank #58 in the 2016 list of the 100 most promising Swiss startups. Please check for more details ...
Topadur Pharma
... been selected among Switzerland's most promising scale-ups in 2022. Huge thanks to everyone of our team ... selected among Switzerland's most promising scale-ups in 2022. Huge thanks to everyone of our team ... Dokument herunterladen https://www.top100startups.swiss/On-the-road-to-growth-Switzerlands-most- promising ...
CSL Vifor
https://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor
8952 Schlieren, Zürcherstrasse 39D
+41 58 851 80 00
Pioneer in iron-based therapies, CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies, with a history dating back to 1872, when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, Switzerland. Since then, we have proven our ability to identify and serve therapeutic areas and patients with significant unmet medical need. Building on our heritage and expertise in iron deficiency therapy, and together with our joint company Vifor Fresenius Medical Care Renal Pharma, today we have a strong and rapidly growing presence in nephrology, and we are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease.
CSL Vifor
Zürcherstrasse 39D
8952 Schlieren
135 Ergebnisse für "promising" unter CSL Vifor
Early Careers at CSL
... your degree, it's never too soon to consider CSL for your Promising FUTURE. Find yours here ... your degree, it's never too soon to consider CSL for your Promising Future! Early Careers at CSL ... CSL for your Promising FUTURE. Find yours here. Apprenticeships Prepare for your professional future ...
CSL Annual Report 2022 – Page 40
... US) Providing promising futures for employees At CSL, we want all employees to pursue their career ... aspirations and reach their potential. We launched our Promising FUTURES channel to reflect our commitment to ... .] CSL’s Disability Profile (Germany an US) Providing promising futures for employees At CSL, we want all ... employees to pursue their career aspirations and reach their potential. We launched our Promising FUTURES ...
CDR-Life AG
8810 Horgen, Tödistrasse 46
CDR-Life is a Zurich-based biotech company that discovers and develops innovative medicines for the treatment of high need diseases. We invent and develop therapeutic antibody fragments with a focus on immuno-oncology and ophthalmology.
CDR-Life AG
Tödistrasse 46
8810 Horgen
3 Ergebnisse für "promising" unter CDR-Life AG
CDR-Life
... designs, produces, and optimizes new antibodies in a variety of formats for the development of promising ... designs, produces, and optimizes new antibodies in a variety of formats for the development of promising ...
News - CDR-Life
... intracellular antigens in tumor cells is a very promising approach to achieve better efficacy and safety ... novel and promising immunotherapies across a range of indications.” Prior to joining CDR-Life, Mr ... targeting of intracellular antigens in tumor cells is a very promising approach to achieve better efficacy ... portfolio of novel and promising immunotherapies across a range of indications.” Prior to joining CDR-Life ...
University Hospital Zurich, Research and Education Office
https://www.usz.ch/forschung/Seiten/default.aspx
8091 Zürich, Rämistrasse 100
The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.
University Hospital Zurich, Research and Education Office
Rämistrasse 100
8091 Zürich
85 Ergebnisse für "promising" unter University Hospital Zurich, Research and Education Office
... ) hyperscanning is a promising new method able to asses the brain-to-brain coupling during different inter ...
... promising positon-emitting radiotracers for use in the clinic. OVERVIEW Our research is highly ... , to ensure that our most promising radiotracers are translated efficiently so patients can benefit as ... promising positon-emitting radiotracers for use in the clinic. OVERVIEW Our research is highly ... , to ensure that our most promising radiotracers are translated efficiently so patients can benefit as ...
